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ABSTRACT
Ets transcription factors play important roles during
the development and maintenance of the haemato-
poietic system. One such factor, Elf-1 (E74-like
factor 1) controls the expression of multiple essen-
tial haematopoietic regulators including Scl/Tal1,
Lmo2 and PU.1. However, to integrate Elf-1 into
the wider regulatory hierarchies controlling haem-
atopoietic development and differentiation, regula-
tory elements as well as upstream regulators of
Elf-1 need to be identified. Here, we have used
locus-wide comparative genomic analysis coupled
with chromatin immunoprecipitation (ChIP-chip)
assays which resulted in the identification of five
distinct regulatory regions directing expression of
Elf-1. Further, ChIP-chip assays followed by func-
tional validation demonstrated that the key haem-
atopoietic transcription factor PU.1 is a major
upstream regulator of Elf-1. Finally, overexpression
studies in a well-characterized erythroid differenti-
ation assay from primary murine fetal liver cells
demonstrated that Elf-1 downregulation is neces-
sary for terminal erythroid differentiation. Given the
known activation of PU.1 by Elf-1 and our newly
identified reciprocal activation of Elf-1 by PU.1,
identification of an inhibitory role for Elf-1 has sig-
nificant implications for our understanding of how
PU.1 controls myeloid–erythroid differentiation. Our
findings therefore not only represent the first report
of Elf-1 regulation but also enhance our understand-
ing of the wider regulatory networks that control
haematopoiesis.
INTRODUCTION
The formation and subsequent diﬀerentiation of haemato-
poietic stem cells (HSCs) is tightly controlled requiring the
sequential and coordinated action of multiple transcrip-
tion factors. The Ets family is one of the largest families
of transcriptional regulators involved in the regulation of
haematopoiesis. All Ets proteins contain a region of
conserved sequence, corresponding to the ETS domain,
which constitutes the DNA binding domain and recog-
nizes a core GGAW sequence in the major groove of
DNA. Binding of ETS proteins to this sequence is often
facilitated by synergistic interaction with transcriptional
partners on composite DNA elements (1).
The Ets-transcription factor Elf-1 was originally cloned
from a human T-cell cDNA library by hybridization with
a probe encoding the DNA binding domain (ETS domain)
of the human Ets-1 cDNA (2). Based on its preferential
expression in embryonic lymphoid organs (thymus and
spleen), a wide variety of epithelial cells and fetal liver
(3) as well as in adult haematopoietic tissues, including
thymus, spleen and bone marrow (4,5), Elf-1 emerged as
a potential key regulator of haematopoietic gene
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shown to be a direct upstream regulator of genes import-
ant for haematopoiesis such as Scl, Fli-1, Lyl-1, Runx1
and Lmo2 (6–11). Like other members of the Ets family
such as Ets-1 and Ets-2, no major haematopoietic pheno-
types have been observed in Elf-1
 /  mice (12). However,
given that Elf-1, like Ets-1, is a member of a small sub-
family, a likely explanation for the lack of a strong pheno-
type in loss of function assays is compensation by other
Ets proteins which are also known to be expressed in the
haematopoietic system.
Elf-1 has also been shown to be important for blood
vessel development, a process that is closely linked to early
haematopoiesis during embryonic development. Elf-1 has
been reported to take part in the transcriptional control of
major regulators of blood vessel development such as
Tie1, Tie2, angiopoietin-2, the vascular endothelial
growth factor receptor 1 (VEGFR1), the endothelial
nitric-oxide synthase (eNOS) and endoglin (3,13–16).
Moreover, a recent landmark study demonstrated that
Elf-1 constitutes a potentially very attractive target for
the development of new cancer therapies as systemic ap-
plication of an ELF-1 blocking peptide was able to inhibit
tumour angiogenesis in a mouse model of melanoma (17).
Functional activity of Ets proteins is modulated at
multiple levels. For example, it is known that ELF-1
appears in the cytoplasm as a 80 KDa protein that is
O-glycosylated and phosphorylated in order to be
translocated into the nucleus where it can be detected as
a 98 KDa protein. After dephosphorylation, the protein is
degraded through the proteasome pathway (18–20). In
resting T cells, ELF-1 binds to the underphosphorylated
form of the retinoblastoma protein pRb and after T-cell
activation, the phosphorylation of pRb results in the
release of ELF-1 (21).
Despite its function as an important transcriptional
regulator in both blood and endothelium, nothing is
known about the transcriptional regulation of the Elf-1
gene itself. Consequently, the position of Elf-1 within
the wider regulatory networks controlling blood cells
had remained obscure. In this study, we have identiﬁed
and characterized ﬁve regulatory elements within the
Elf-1 locus. Four regulatory regions functioned as pro-
moters and one region as a lineage-speciﬁc enhancer.
Furthermore, we showed that the transcription factor
PU.1 plays a major role in the regulation of Elf-1 and
that downregulation of Elf-1 is important for terminal
erythroid diﬀerentiation.
MATERIALS AND METHODS
Sequence analysis and custom arrays
Genomic Elf-1 sequences were downloaded from
Ensembl, aligned using multi-Lagan (22) and displayed
using mVista (23). Primers to generate the Elf-1 oligo
tiling array were designed using Primer3 (24) on repeat
masked sequence spanning Elf-1 and ﬂanking genes
(chr14:74160804–74269970, coordinates in build mm7).
Oligos were spotted in triplicate using a BioRobotics
MicroGrid II Total Array System. Array design ﬁles
have been submitted to ArrayExpress.
ChIP-chip assays
ChIP assays were performed as previously described (25).
Brieﬂy, cells were treated with formaldehyde and
cross-linked chromatin was sonicated to 300bp averaged
size. Immunoprecipitations were performed using
anti-acetyl histone H3 antibody (Millipore, 06-599),
anti-H3 trimethyl lysine 4 (Millipore, 04-745 and gift
from Dr L. O’Neill, Birmingham, UK) and anti-PU.1
(Santa Cruz, sc-352X). ChIP material was labelled with
Cy3 and Cy5 ﬂuorochromes and hybridized as described
(26). Microarrays were scanned using an Agilent scanner
and median spot intensities quantiﬁed using GenePix Pro
6.0 with background subtraction. A Perl script was de-
veloped to normalize the resulting data and calculate
mean ratios of normalized ChIP signals over input (27)
using the triplicate values on the array. Resulting data
were plotted using the Variable WidthBar Graph
Drawer (http://hscl.cimr.cam.ac.uk/genomic_tools.html).
All experiments have been deposited in ArrayExpress
with accession numbers E-MEXP-2664, E-MEXP-2665
and E-MEXP-2666.
Gene expression analysis
Total RNA was isolated using Tri-Reagent
(Sigma-Aldrich, Dorset, UK) according to the manufac-
turer’s instructions. Contaminating genomic DNA was
removed by DNAseI treatment with Turbo DNA free
(Applied Biosystems/Ambion, Warrington, UK). Total
RNA (125ng) was used for cDNA synthesis, using
oligo(dT) 17-mer primer and MMLV reverse transcriptase
(Sigma-Aldrich). Mouse Elf-1, mouse PU.1 and mouse 18s
mRNA levels were measured by real-time PCR using the
primer sets listed in Supplementary Table S1. Relative ex-
pression was calculated as a ratio to the 18s signal.
Cell culture, reporter constructs and transfection assays
The myeloid progenitor cell line 416B, murine erythroleu-
kaemia cell line F4N, endothelial cell line MS1 and the
T-cell line BW5147 were maintained as previously
described (28,29). Fetal liver and adult thymus cell suspen-
sions were obtained by direct pipetting of freshly dissected
tissues from mice. Elf-1 luciferase reporter constructs were
ampliﬁed from mouse genomic DNA using primers listed
in Supplementary Table S1, conﬁrmed by sequencing and
cloned into pGL2basic (Promega, Southampton, UK).
These regions were selected based on the combined
results of comparative genomics and ChIP-chip experi-
ments (Supplementary Figures S1–S5). Cell lines were
stably transfected by electroporation as described (29).
G418 or puromycin was added 24h post-transfection
and cells were assayed 7–27 days later, depending on the
cell line. For transactivation assays, 293T cells were trans-
fected with 1mg ‘luciferase’ construct in combination with
3mg pcDNA3mPU.1 (generous gift from Dr J. Frampton,
Birmingham, UK) or the empty vector pcDNA3 as
control using ProFection Mammalian Transfection
System-Calcium Phosphate (Promega). Each transfection
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In vitro erythroid diﬀerentiation assay
In vitro erythroid diﬀerentiation assays were performed as
previously described (30,31). Brieﬂy, livers from E14.5
(C57Bl/6   CBA) F1 murine embryos were extracted by
blunt dissection and homogenizsed. Lineage-negative
haematopoietic progenitor cells were isolated using the
MACS Murine Lineage Cell Depletion Kit (Miltenyi
Biotec GmbH, Gladbach, Germany) according to the
manufacturer’s instructions. 2 10
5 lineage-negative
cells were plated onto ﬁbronectin coated 12-well plates
(BD Discovery Labware, Bedford, MA, USA) and
grown in Erythroid Diﬀerentiation Medium [IMDM sup-
plemented with 15% fetal bovine serum, 1% detoxiﬁed
bovine serum albumin (BSA) (both from Stem Cell
Technologies, Vancouver, Canada), 600mg/ml
holo-transferrin (Sigma-Aldrich), 10mg/ml recombinant
human insulin (Sigma-Aldrich), 2mM L-glutamine,
10
 4Mb-mercaptoethanol, and 2U/ml human recombin-
ant erythropoietin].
Retroviral transfection
Plasmid containing murine whole-length Elf-1 cDNA (6)
was digested with PstI, blunted with T4 polymerase,
digested again with XhoI and subcloned into a retroviral
overexpression vector containing MSCV pGKprom-
Puro-IRES-EGFP (PIG). Retrovirus production was
carried out using the pCL-Eco Retrovirus Packaging
Vector (Imgenex, San Diego, CA, USA) and the 293T
cell line. Murine fetal liver cells were infected with retro-
virus by centrifugation at 2000r.p.m. at 30 C for 1.5h
with 4mg/ml polybrene (Sigma-Aldrich) after which the
retroviral supernatant was replaced with Erythroid
Diﬀerentiation Medium (30).
Flow cytometry analysis and cell sorting
Samples for FACS analysis were stained using antibodies
against the surface markers Ter119 [APC conjugated, 1 in
100 dilution] (BD, Oxford, UK) and CD71 [PE
conjugated, 1 in 100 dilution] (BD). Dead cells were
excluded using the 7-aminoactinomycin (7AAD) stain.
All analysis was performed using a FacsCalibur analyser
(BD) and sorting was performed using a Dakocytomation
MoFlo cell sorter.
RESULTS
Locus-wide comparative genomic analysis identiﬁes ﬁve
non-coding conserved regions representing candidate Elf-1
regulatory elements
Cross-species sequence conservation of non-coding
regions has been successfully used in the past to identify
regulatory elements (27,32). To locate candidate regula-
tory elements within the mElf-1 gene locus, we
compared the human, dog and opossum Elf-1 loci to
109kb of the mouse locus containing the entire Elf-1
gene and extending into upstream and downstream
ﬂanking genes. All coding regions were highly conserved
between species analysed (Figure 1A). Non-coding
sequence conservation was more limited but comparison
with the opossum sequence revealed ﬁve highly conserved
non-coding regions that represented candidate regulatory
elements of mElf-1 gene. Four of those regions were
located 55, 21, 14 and 8.5kb upstream of the ATG start
codon of the open reading frame and the ﬁfth region was
located just upstream of the start codon which from here
on will be referred to as the proximal region.
Although Elf-1 is expressed in most haematopoietic
cells (33), levels vary between cell types. In order to
identify cellular systems for functional validation of can-
didate regulatory elements, expression levels of Elf-1 were
assessed in diﬀerent cell types (Figure 1B). We analysed
two sources of primary cells (E13.5 fetal liver and whole
adult thymus) and four diﬀerent cell lines: F4N (erythro-
leukaemia), 416B (early myeloid progenitor), BW5147
(T-lymphoid) and MS1 (endothelial). Finally, we also
included in the study the embryonic stem (ES) cell line
HM-1 since ES cells express low levels of Elf-1 mRNA
(Supplementary Figure S6). As shown in Figure 1B, all
cell types expressed signiﬁcant levels of Elf-1 mRNA
when compared to the ES cell line HM-1. Particularly,
high expression was detected in the whole adult thymus
and in the myeloid progenitor cell line 416B.
Locus-wide ChIP-chip analysis identiﬁes ﬁve Elf-1
candidate regulatory elements
We had previously shown that the combination of
locus-wide comparative genomics and ChIP-chip
analysis provides an eﬀective strategy for the identiﬁcation
of bona ﬁde regulatory elements (16,27). We therefore
performed ChIP-chip analysis using a 109kb tiling array
that spanned the Elf-1 locus and ﬂanking genes with chro-
matin prepared from the four Elf-1 expressing cell lines
(erythroleukaemia F4N, myeloid progenitor 416B,
T-lymphoid BW5147 and endothelial MS1) as well as
two sources of primary cells (E11.5 fetal liver and
whole-adult thymus). Acetylation of histone H3 lysine 9
(H3AcK9) is a histone mark associated with an open chro-
matin conformation and is generally observed at pro-
moters and enhancers of active genes. The acetylation
pattern across the Elf-1 locus in the highly expressing
myeloid progenitor cell line 416B included an enriched
region close to the ATG start codon of the gene. This
region was also enriched in the endothelial and
T-lymphoid cell lines but it was practically absent in the
erythroid cell line. Myeloid and T-lymphoid cell lines pre-
sented a broad enriched region that co-localized with the
 21 and  14 regions identiﬁed by comparative genomic
analysis, whereas the endothelial and erythroid cell lines
only showed H3K9 acetylation around the  21 region. In
the vicinity of the 50-ﬂanking gene Wbp4, around 55kb
upstream of the ATG start codon, another enriched
region was detected in all cell types analysed. Therefore,
with the exception of the  8.5 region all homology peaks
identiﬁed by comparative genomics displayed histone
H3K9 acetylation. Consistent with its predominant eryth-
roid nature, the pattern of acetylation found in fetal liver
Nucleic Acids Research, 2010,Vol.38, No. 19 6365was most similar to erythroid F4N cells and, similarly, the
pattern for the thymus resembled that of the T-lymphoid
BW5147 cells. Interestingly, a region 49kb upstream of
the Elf-1 ATG ( 49 region) showed substantial levels of
acetylation in low-expressing Elf-1 cells, while it was
largely absent in highly expressing cells. This region is
conserved in human and dog but it is not conserved in
opossum. Taken together therefore, comparative
genomics combined with histone acetylation ChIP-chip
analysis identiﬁed ﬁve candidate regulatory regions,
namely the  55,  49,  21  14 and proximal regions
(Figure 2).
Four of the ﬁve Elf-1 histone acetylation peaks represent
candidate alternative promoters
Interrogation of EST databases as well as the database
of transcriptional start sites (DBTSS) suggested that
the acetylation peaks identiﬁed above might represent al-
ternative promoters of the Elf-1 gene (Supplementary
Figure S7). We therefore also assessed trimethylation of
histone H3 lysine 4 (H3Me3K4) by ChIP-chip analysis
(Figure 3). This chromatin modiﬁcation is speciﬁcally
associated with active promoter regions and the results
correlated very closely to those previously obtained
using antibodies against acetylation. When the high
Elf-1 expressing myeloid cell line 416B was analysed, a
high enrichment could be detected for the regions corres-
ponding to the  55,  21 and proximal elements but not
for the  14 element, suggesting that this element could act
as an enhancer within this locus. As in the acetylation
analysis, the trimethylation patterns of fetal liver and
erythroid F4N cells were similar, showing robust enrich-
ments at the  55 and  49 regions. T-lymphoid cells and
adult thymus showed similar patterns, with peaks at the
 55 and  21 regions and the endothelial MS1 cell line
only showed major enrichment at the  55 region.
In summary, the ChIP-chip survey allowed us to
identify ﬁve candidate regulatory elements:  55,  49,
 21,  14 and proximal regions. Four of these regions
( 55,  49,  21 and proximal) displayed both acetylation
and trimethylation marks suggesting that they represent
alternative Elf-1 promoters. Transcripts that could be
promoted by three of these regions ( 55,  21 and
proximal) have been previously reported in mouse or rat
(Supplementary Figure S7). Although the region  49 also
displayed both acetylation and trimethylation marks, no
Figure 1. Identiﬁcation of ﬁve non-coding conserved regions by comparative analysis. (A) Sequence conservation of the Elf-1 locus. MVista rep-
resentation of sequence conservation across the mouse Elf-1 locus showing mouse/human, mouse/dog and mouse/opossum alignments. The conser-
vation plots show regions with at least 50% of conservation (y-axis) across the 109kb tiling path spanning the mouse Elf-1 locus. Peaks of sequence
conservation in coding regions of the genome are shown in dark grey, those in transcribed but not translated regions (30UTR and 50UTR) are shown
in pale grey. Neighbouring genes are also depicted. Arrows indicate the direction of transcription. Positions of the conserved regions are named
relative to the ATG of Elf-1.( B) Elf-1 expression in haematopoietic cell lines. Real-time PCR analysis of mouse Elf-1 expression in the murine
erythroleukaemia cell line F4N, the myeloid progenitor cell line 416B, the T-lymphoid cell line BW5147, the endothelial cell line MS1, the ES cell line
HM-1 as well as in two sources of primary cells (fetal liver and whole-adult thymus). Values are expressed relative to m18s expression. Error bars
indicate SD.
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reported so far. DNAse I hypersensitivity analysis by
ChIP-chip performed in the primary tissues fetal liver
and thymus showed that this region was highly hypersen-
sitive (Supplementary Figure S8). Taken together, these
results are consistent with the hypothesis that this region
could represent an as yet unidentiﬁed promoter involved
in Elf-1 regulation. Finally, one region ( 14) only carried
acetylation marks, suggesting that it may function as an
enhancer. Four of these regions overlapped with regions
identiﬁed in the comparative genomic analysis, further
validating these results.
The Elf-1 locus contains four distinct regions with
promoter activity
To validate the results obtained by integration of the com-
parative genomic sequence analysis and ChIP-chip
approaches, the four candidate promoter regions were
cloned into the pGL2 basic luciferase vector and stably
transfected into the erythroleukaemia cell line F4N,
myeloid progenitor cell line 416B, the T-lymphoid cell
line BW5147 and endothelial cell line MS1. In three of
the four cell lines, the proximal element showed the
highest promoter activity. However, diﬀerent proﬁles
were observed according to the proportional activity of
the diﬀerent regions (Figure 4A). In the high-expressing
myeloid cell line 416B and in T-cell line BW5147, proximal
and  21 elements presented higher activity than the other
two elements. Proximal and  55 elements showed strong
activity in the F4N cell line deﬁning a diﬀerent proﬁle.
Finally, in the endothelial cell line MS1, proximal,  21
and  55 regions had similar activity.
The activity of the  49 element was low in all four cell
lines analysed, although this region was acetylated and
methylated in our ChIP-chip assays. Genome-wide
ChIP-Seq binding proﬁles for GATA-1 have been
reported in erythroid cells (34). We extracted the data cor-
responding to the Elf-1 locus that demonstrated speciﬁc
binding of GATA-1 to the  49 region (Supplementary
Figure S9). We therefore tested whether this element
might in fact be an enhancer and generated reporter con-
structs with the  49 element cloned up- and downstream
of the luciferase gene under the control of a minimal
region of the SV40 promoter (pGL2 promoter). No sig-
niﬁcant enhancer activity could be detected in any of the
cell lines when this element was present (data not shown).
However, a reproducible decrease in the activity can be
detected in F4N when this element was located down-
stream of the reporter gene. Then, antisense promoter
activity of this element was also tested to explore the
Figure 2. Locus-wide ChIP-chip of acetylation of histone H3 lysine 9 identiﬁes ﬁve potential regulatory elements. MVista representation of mouse/
human sequence conservation is shown on the top together with all candidate regulatory elements. Annotations as in Figure 1A. ChIP-chip for the
murine erythroleukaemia cell line F4N, the myeloid progenitor cell line 416B, the T-lymphoid cell line BW5147, the endothelial cell line MS1, E11.5
fetal murine liver and adult murine thymus. Enrichment values are calculated as fold enrichment over the mean intensity across the whole locus and
expressed as log base 2.
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activity was detected in any of the four cell lines when
stably transfected with this construct in an antisense orien-
tation (data not shown).
The Elf-1  14 region functions as a
lineage-speciﬁc enhancer
The  14 region is highly conserved between species and it
is strongly acetylated in several cell types, which suggests
an important function for this region in the regulation of
the locus. As it only carried acetylation marks, we
hypothesized it may function as an enhancer. Thus, we
tested the enhancer activity of this element when cloned
downstream of the luciferase gene under the control of the
SV40 minimal promoter (pGL2 promoter). Stable trans-
fection assays using 416B myeloid progenitor and
BW5147T-lymphoid cell lines demonstrated that the
 14 element functioned as a very strong enhancer in the
myeloid progenitor cell line 416B and showed moderate
activity in the T-lymphoid cell line BW5147 (Figure 4B).
In contrast, the  14 element showed no activity in the
F4N erythroleukaemia and MS1 endothelial cell lines.
These results were entirely consistent with the ChIP-chip
analysis which had shown cell-type-speciﬁc acetylation
and therefore demonstrate that the  14 region contains
a lineage-speciﬁc transcriptional enhancer element.
PU.1 binds to  21 and  14 elements in vivo and controls
the activity of regulatory elements of Elf-1
We also explored which transcription factors could be re-
sponsible for the activation of the newly identiﬁed regula-
tory elements of Elf-1 and performed ChIP-chip using
antibodies directed against known key haematopoietic
transcription factors such as PU.1, SCL and GATA2.
PU.1 is a transcription factor known to be important for
haematopoiesis that has frequently been reported to
co-operate with Elf-1 in gene regulation (6,35–37). In
addition, interrogation of the Supplementary Data for
a recent large-scale system biology analysis of myeloid
diﬀerentiation (38) demonstrated that knock-down of
PU.1 expression in the myeloid cell line THP-1 leads to
a reduction of Elf-1 gene expression (Supplementary
Figure S10A). In order to analyse whether PU.1 is
directly involved in the transcriptional regulation of
Elf-1, we performed ChIP-chip assays in the Elf-1
high-expressing cell line 416B using an antibody against
PU.1 (Figure 5A). Binding of PU.1 can be detected at
both the  21 and  14 elements. ChIP-chip analysis with
antibodies against GATA-2 and SCL were also performed
but no binding was detected across the Elf-1 locus even
though clear binding peaks were observed in regions from
the Scl locus included on the same array as positive
controls (data not shown).
Figure 3. Locus-wide ChIP-chip of trimethylation of histone H3 lysine 4 identiﬁes four potential promoter elements. MVista representation of
mouse/human sequence conservation is shown on the top together with all candidate regulatory elements. Annotations as in Figure 1A. ChIP-chip
for the murine erythroleukaemia cell line F4N, the myeloid progenitor cell line 416B, the T-lymphoid cell line BW5147, the endothelial cell line MS1,
whole E11.5 fetal murine liver and whole-adult murine thymus. Enrichment values are calculated as fold enrichment over the mean intensity across
the whole locus and expressed as log base 2.
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activation of Elf-1 by PU.1, transactivation assays were
performed in human embryonic kidney 293T cells where a
PU.1 expressing plasmid was co-transfected with plasmids
carrying the four promoter elements and the enhancer
region. No transactivation could be detected on the
proximal,  49 or  55 elements but a signiﬁcant increase
in luciferase activity was detected when the  21 element
and PU.1 were co-transfected (Figure 5B). We failed to
detect transactivation on the  14 element (data not
shown), likely because additional factors and/or integra-
tion into chromatin may be required. The transactivation
assays were therefore not only consistent with the
ChIP-chip data by showing speciﬁc activation by PU.1
at the only promoter identiﬁed by ChIP-chip to be
bound by PU.1, but also importantly validated PU.1 as
an upstream activator of Elf-1 expression. As an addition-
al validation of the regulation of Elf-1 by PU.1, we
performed transient co-transfections of the  21 element
with a PU.1 knock-down or control construct in
the myeloid progenitor cell line 416B. These experiments
revealed a speciﬁc reduction of the activity of the
Elf-1  21 promoter when PU.1 levels are reduced
thus corroborating further the role of PU.1 as an
upstream regulator of Elf-1 expression (Supplementary
Figure S10B).
Elf-1 downregulation is important for
erythroid diﬀerentiation
The enrichment levels obtained when using H3Me3K4
antibodies for the erythroleukaemia cell line F4N and
fetal liver were modest, especially when compared to
myeloid progenitor cells. Since downregulation of other
Ets factors is important for erythroid development
(39,40), we therefore investigated whether this may also
be true for Elf-1. Erythroid diﬀerentiation can be moni-
tored by labelling fetal liver cells for erythroid-speciﬁc
TER119 and non-erythroid-speciﬁc transferrin receptor
(CD71; 30). To investigate Elf-1 expression during
murine fetal liver erythropoiesis, E14.5 fetal liver cells
Figure 4. Functional validation of candidate regulatory elements. Promoter (A) and enhancer (B) activity of candidate regulatory regions was
assayed. Stable transfection of the murine erythroleukaemia cell line F4N, the myeloid progenitor cell line 416B, the T-lymphoid cell line
BW5147, the endothelial cell line MS1 with luciferase reporter constructs containing Elf-1 candidate regulatory elements. Mean and SEM for
two (A) or three (B) independent transfections (each one performed in triplicate) are shown. (A)  55,  49,  21 and proximal elements of Elf-1
were inserted upstream of a luciferase reporter gene. Values are expressed relative to empty vector, pGL2 basic. (B) A 550-bp length of DNA
corresponding to the Elf-1  14 element was inserted downstream of a luciferase reporter gene under the transcriptional control of the minimal SV
promoter. Values are expressed relative to empty vector, pGL2 promoter.
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sequential phases of erythroid diﬀerentiation (31) and
the levels of PU.1 and Elf-1 transcripts in each population
determined. Expression levels of mPU.1 and mElf-1 were
determined by real-time qPCR in CD71
medTER119
low,
CD71
highTER119
med/low, CD71
highTER119
high and
CD71
med/low TER119
high cells, corresponding to regions
RI–RIV, respectively (Figure 6A and Supplementary
Figure S11A). The CD71
lowTER119
high population are
largely enucleated cells, and were therefore excluded
from this analysis. Interestingly, a very similar pattern of
downregulation was seen for PU.1 and Elf-1, which was
consistent with our previous results identifying PU.1 as an
upstream regulator of Elf-1 and also suggesting that
downregulation of Elf-1 may be necessary for erythroid
diﬀerentiation.
To further explore the biological signiﬁcance of our
results, we took advantage of an extensively validated
in vitro culture system that supports terminal erythroblast
proliferation and diﬀerentiation in a manner that closely
mimics the in vivo terminal proliferation and maturation
of erythroid cells (30). In this system, diﬀerentiation of
CFU-E progenitors can be followed step by step and in
a quantitative manner using ﬂow cytometry. Essentially,
lineage negative E14.5 fetal liver cells are puriﬁed and
cultured in vitro. Diﬀerentiation is then analysed at
various time points by double labelling for TER119 and
CD71, which makes it possible to distinguish at least ﬁve
distinct populations of cells: CD71
medTER119
low that
contains primitive progenitor cells and proerythroblasts;
CD71
highTER119
low, proerythroblasts and early
basophilic erythroblasts; CD71
highTER119
high, early and
late basophilic erythroblasts; CD71
medTER119
high
chromatophilic and orthocromatophilic erythroblasts;
CD71
lowTER119
high late orthocromatophilic erythro-
blasts and reticulocytes (Figure 6B and Supplementary
Figure S11B, regions R1–R5, respectively). TER119
high
surface expressing cells constitute committed erythroid
cells. During the course of erythroid diﬀerentiation, a
decrease of cell size is also observed.
We therefore overexpressed mElf-1 cDNA in puriﬁed
TER119
low cells with the use of a retroviral vector
(MSCV-Elf-1-PGKprom-puro-IRES-GFP) that also
encodes GFP. Thus, transduced cells were labelled with
GFP and overexpressed mElf-1 (Supplementary Figure
S11C); uninfected GFP
  cells served as internal controls.
We then analysed erythroid-diﬀerentiation proﬁles in the
in vitro culture system. Figure 6B–D show the results of a
representative experiment. Overexpression of Elf-1 did not
cause any signiﬁcant changes in FACS proﬁles after 24h
of diﬀerentiation. After 48h of diﬀerentiation, however,
overexpression of Elf-1 impaired terminal erythroid diﬀer-
entiation, as evidenced by the statistically signiﬁcant
(Student’s t-test, P   0.05) accumulation of more
immature cells in R3 at the expense of more mature
cells in R4 when compared to the empty vector control
(Figure 6B and D). Moreover, a signiﬁcantly larger pro-
portion of Elf-1 transduced cells displayed a larger cell size
consistent with the presence of more immature cells
(Figure 6C). These results indicate that downregulation
of Elf-1 is important for terminal diﬀerentiation of
erythrocytes.
Figure 5. PU.1 regulates expression of Elf-1.( A) PU.1 ChIP-chip assays. MVista representation of mouse/human sequence conservation is shown on
the top together with all candidate regulatory elements. Annotations are the same as in Figure 1A. ChIP-chip for the myeloid progenitor cell line
416B across the 109kb tiling path spanning the mouse Elf-1 locus. Enrichment values are expressed as fold above mean intensity across the locus.
(B) Transactivation of candidate regulatory elements by PU.1. Transient co-transfections of 293T cells with luciferase reporter constructs containing
Elf-1 candidate regulatory elements in combination with either pcDNA3mPU.1 (PU.1) or the empty vector pcDNA3 (control). Values are expressed
relative to the control, pcDNA3. Mean and SEM for two independent transfections (each one performed in triplicate) are shown.
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Reconstruction of regulatory networks is essential to
understand the complex and dynamic interactions
between the multiple regulators that control the develop-
ment and subsequent diﬀerentiation of blood stem cells.
Deﬁnition of transcriptional regulatory networks requires
both knowledge of the transcription factors involved and
also the DNA sequences to which they bind. Therefore,
identiﬁcation and subsequent functional analysis of gene
regulatory elements remains an essential area of research,
in particular when it serves to clarify upstream hierarchies
of key regulators thus providing ﬁrm anchor points for
major regulatory network nodes. In this article, we have
analysed the transcriptional regulation of Elf-1, which
itself encodes a major transcriptional regulator of blood
and endothelial cells.
In this study, an integrated analysis of the Elf-1 locus
using comparative genomic analysis, ChIP-chip and func-
tional studies allowed us to deﬁne ﬁve distinct regulatory
regions spread over 50kb, including the identiﬁcation of a
lineage-speciﬁc enhancer element. The comparative
genomic analysis showed the presence of ﬁve regions
conserved between mouse, human, dog and opossum. Of
these conserved regions, four contained high levels of
acetylation at H3K9, a chromatin mark associated with
areas of open chromatin. One additional region,
conserved between mouse, human and dog but not
opossum, was also enriched for this chromatin mark.
Further ChIP-chip assays were performed to analyse
trimethylation of lysine 4 on the tail of histone H3, a
modiﬁcation that is associated with recently transcribed
regions. These experiments led to the discovery that four
of the ﬁve regions identiﬁed by elevated histone acetyl-
ation display promoter activity in functional assays. The
ﬁfth region, which carried active chromatin marks but no
transcription marks, was validated as an enhancer in func-
tional analysis. We also demonstrate that PU.1 is a major
upstream regulator of Elf-1 since PU.1 binding could be
detected by ChIP-chip in one of the four promoter
regions. We validated this result with functional analysis
Figure 6. Overexpression of Elf-1 impairs terminal erythroid diﬀerentiation. (A) Expression of PU.1 and Elf-1 during in vivo fetal liver terminal
erythroid diﬀerentiation. Real-time PCR analysis of mouse PU.1 and Elf-1 expression in three populations of murine E14.5 fetal liver cells: (RI)
CD71
medTER119
low, (RII) CD71
highTER119
med/low and (RIII) CD71
highTER119
high; sorted by ﬂow cytometry and representing sequential stages of
erythroid diﬀerentiation (Supplementary Figure S11A). m18s ribosomal RNA gene expression was used to normalize expression of each population.
Values are expressed relative to the expression at RI stage. Error bars indicate SD. (B) Representative FACS plots for Ter119 and CD71 expression
during in vitro diﬀerentiation in lineage negative E14.5 fetal liver cells overexpressing Elf-1 or a control (PIG) vector after 24h (Day 1) or 48h (Day
2). Five populations corresponding to stages of erythroid diﬀerentiation from progenitors to enucleated cells are gated: (R1) CD71
medTER1119
low,
(R2) CD71
highTER119
low, (R3) CD71
highTER1119
high, (R4) CD71
medTER1119
high and (R5) CD71
lowTER1119
high (Supplementary Figure S11B).
Percentage of GFP
+ cells in each of these stages are indicated. (C) Representative FACS plots for cellular size in lineage negative E14.5 fetal liver
cells overexpressing Elf-1 (black line) or a control (PIG) (grey shaded area) vector after 24h (Day 1) or 48h (Day 2) of in vitro culture. (D) Bar charts
indicating the proportion of cells at each of the ﬁve stages of erythroid diﬀerentiation (R1–R5) after 24h (Day 1) and 48h (Day 2) of in vitro culture
of lineage negative E14.5 fetal liver cells retrovirally transfected with an overexpressing Elf-1 or control (PIG) vector. Representative plot (mean and
SD) for one of ﬁve independent experiments, each one performed in triplicate. P 0.05 (Student’s t-test) are indicated with an asterisk.
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The expression proﬁle of Elf-1 has been widely analysed
during embryonic development. In chicken embryos, Elf-1
is expressed along the lining of the larger caliber and
smaller caliber branching blood vessels, in the developing
heart at Day 10 (3), in the developing dorsal aorta of the
mouse embryos (17), in embryonic lymphoid organs
(thymus and spleen) and a wide variety of epithelial cells
and fetal liver (3). Elf-1 is speciﬁcally expressed in multiple
haematopoietic cell types (Supplementary Figure S6) and
we now show for the ﬁrst time that Elf-1 downregulation
is important for erythroid diﬀerentiation. Scl and Lmo2
are known targets of Elf-1, and together with GATA-1,
LDB1 and E2A constitute the major transcriptional acti-
vator complex operating in erythroid cells (41). In light of
our ﬁndings that Elf-1 downregulation is critical for eryth-
roid diﬀerentiation, Elf-1 activation of Lmo2 and Scl
therefore seems at ﬁrst glance contradictory. However,
Elf-1 speciﬁcally activates only those regulatory elements
within Scl and Lmo2 that are responsible for directing the
expression of these genes in endothelial and blood stem/
progenitor cells. In contrast, the erythroid speciﬁc regula-
tory elements of Scl and Lmo2 require autoregulation
through Scl/Lmo2 containing complexes (6,7,28). Our
results therefore highlight the need to understand the dy-
namical nature of regulatory hierarchies and the need to
perform functional assays in multiple lineages.
Identiﬁcation of lineage-speciﬁc upstream regulators
therefore will be essential to reconstruct diﬀerentiation
state-speciﬁc regulatory networks as well as state transi-
tions during diﬀerentiation.
The control of myeloid versus erythroid diﬀerentiation
of multipotent progenitors by PU.1 and GATA-1 has
been the subject of extensive investigations (40,42–44).
Current models suggest that PU.1 and GATA-1 are
positive drivers of myeloid and erythroid diﬀerentiation,
respectively, and direct cross-antagonistic interactions
between the two determine myeloid versus erythroid cell
fate choice. Our observations that (i) PU.1 is a direct
upstream activator of Elf-1 in progenitor cells and (ii)
Elf-1 itself inhibits terminal erythroid diﬀerentiation
suggest that the model of PU.1/GATA-1 cross-
antagonism as a simple molecular switch may need to be
revised. Other known myeloid targets of PU.1, such as
c-fms, promote myeloid diﬀerentiation but we now show
that Elf-1 itself actually inhibits erythroid diﬀerentiation.
Elf-1 has been shown to activate the PU.1  14 enhancer
element (45) and is also known to be able to repress
GATA-1 target genes (46,47). It is therefore possible
that Elf-1 exerts its eﬀect largely through enhancing the
antagonistic interaction of PU.1 with GATA-1. To this
end, PU.1 and Elf-1 could also collaborate to directly
repress GATA-1. Elf-1 is known to co-operate and
interact with other members of the GATA family such
as GATA-2 (48) and GATA-3 (49) to promote transcrip-
tion but this does not exclude the possibility that Elf-1
interacts with GATA-1 to inhibit its action or repress its
expression in a similar fashion to PU.1. Moreover, pRb, a
binding partner of Elf-1 (21), is itself intrinsically required
for terminal erythroid diﬀerentiation (50,51) suggesting
that Elf-1 may have a wider role and thus link previously
unsuspected regulators with the phenotype of PU.1
mediated suppression of erythroid diﬀerentiation.
This study reports the ﬁrst description of the transcrip-
tional regulation of the Ets factor Elf-1 and therefore rep-
resents a critical advance in integrating this important
regulator into the wider haematopoietic regulatory
networks. Moreover, identiﬁcation of reciprocal activa-
tion between Elf-1 and PU.1 together with identiﬁcation
of a functional role for Elf-1 as a negative regulator of
terminal erythroid diﬀerentiation have provided import-
ant new insights into the transcriptional control of
myelo-erythroid diﬀerentiation. Therefore, taken
together, these results have expanded our understanding
of haematopoietic regulatory networks and provided new
insights into the molecular mechanisms that control
erythropoiesis.
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